Shares of Chinese biopharmaceutical company I-Mab (IMAB) continued to impress following the recent half-year results for the period ended June 30. The company added more than 27% in market value after posting impressive results. I-Mab has now gained more than 215% since listing on the Nasdaq in January.

The autoimmune disorders and cancer treatment research and development company is one of the companies to benefit from a highly successful initial public offering market this year. Other IPOs that enjoyed a stellar campaign this year include Schrodinger Inc. (SDGR), which gained more than 100% by mid-July before pulling

Aptevo Therapeutics (APVO), a spinoff from Emergent BioSolutions (EBS), focuses on novel oncology (cancer) and hematology (blood disease).

Aptevo currently has four main revenue-generating products. In 2016, although the commercial portfolio revenue jumped by 30% year over year, its loss doubled to $126 million. The sudden rise in operation loss was due to $71 million impairment. I considered this a conservative accounting approach that Aptevo takes.

As of March there was no goodwill left and only $14.5 million in intangible assets. What is interesting is that Aptevo has a lot of cash. It has total cash equivalent of nearly $61

According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Realpage Inc., Anadigics Inc., Emergent BioSolutions Inc. and ScanSource.

Realpage Inc. (RP): Chairman, President and CEO Stephen T. Winn sold 80,000 shares

Winn sold 80,000 shares on Dec. 29 at an average price of $22.53. Realpage, along with its subsidiaries, is a provider of on demand software solutions for the rental housing industry. Realpage has a market cap of $1.76 billion; its shares were traded at around $22.45 with and P/S ratio of 3.82.

Realpage Inc. announced its 2015 third quarter financial results. The

Yum! Brands Inc. (YUM): Chair CEO and Pres David C Novak sold 765,596 Shares